Pricing updated 2019-07-23. Prices are subject to change without notice.
Fenofibrate is an agonist of peroxisome proliferator-activated receptor α (PPARα) with EC50 values of 18 and 30 μM for mouse and human receptors, respectively, in a transactivation assay.1 It is selective for PPARα over PPARγ (EC50s = 300 and 200 μM for mouse and human receptors, respectively) and lacks activity at mouse and human PPARδ at a concentration of 100 μM. In vivo, fenofibrate (50-100 mg/kg) reduces plasma levels of triglycerides, C-reactive protein, and malondialdehyde (MDA) in mice with fructose-induced hypertriglycemia in a dose-dependent manner.2 It decreases glomerular and tubular atrophy and necrosis induced by cisplatin (Item No. 13119) in rat kidney when administered at a dose of 100 mg/kg.3 Fenofibrate also reduces the number of pulmonary lesions induced by 4-nitroquinoline 1-oxide (4-NQO) in lung in Tsumura Suzuki obese diabetic (TSOD) mice.4
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Willson, T.M., Brown, P.J., Sternbach, D.D., et al. The PPARs: From orphan receptors to drug discovery J. Med. Chem. 43(4), 528-550 (2000).
2. Sun, B., Xie, Y., Jiang, J., et al. Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia Lipids Health Dis. 14:27, (2015).
Helmy, M.M., Helmy, M.W., and El-
Kuno, T., Hata, K., Takamatsu, M., et al. The peroxisome proliferator-